BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tseng JC, Chang YC, Huang CM, Hsu LC, Chuang TH. Therapeutic Development Based on the Immunopathogenic Mechanisms of Psoriasis. Pharmaceutics 2021;13:1064. [PMID: 34371756 DOI: 10.3390/pharmaceutics13071064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Borsani E, Buffoli B, Bonomini F, Rezzani R. The Growth Factor Release from a Platelet-Rich Plasma Preparation Is Influenced by the Onset of Guttate Psoriasis: A Case Report. Applied Sciences 2022;12:7250. [DOI: 10.3390/app12147250] [Reference Citation Analysis]
2 Kuptsova DG, Radigina TV, Petrichuk SV, Murashkin NN, Khotko AA, Ivanov RA. Assessment of CD4<sup>+</sup> cells subpopulations with the expressing CD39 and CD73 ectonucleotidases in children with psoriasis. Med immunol 2022;24:587-596. [DOI: 10.15789/1563-0625-aoc-2487] [Reference Citation Analysis]
3 Ujiie H, Rosmarin D, Schön MP, Ständer S, Boch K, Metz M, Maurer M, Thaci D, Schmidt E, Cole C, Amber KT, Didona D, Hertl M, Recke A, Graßhoff H, Hackel A, Schumann A, Riemekasten G, Bieber K, Sprow G, Dan J, Zillikens D, Sezin T, Christiano AM, Wolk K, Sabat R, Kridin K, Werth VP, Ludwig RJ. Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases. Front Med (Lausanne) 2022;9:875492. [PMID: 35755063 DOI: 10.3389/fmed.2022.875492] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
4 Orsmond A, Bereza-Malcolm L, Lynch T, March L, Xue M. Skin Barrier Dysregulation in Psoriasis. Int J Mol Sci 2021;22:10841. [PMID: 34639182 DOI: 10.3390/ijms221910841] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]